The Priority Review

Tag

ABBV-706

1 story

  1. Clinical trials

    AbbVie announces data to be presented at 2026 ESMO Congress

    AbbVie today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. The presentations cover investigational assets such as Temab-A, ABBV-706, ABBV-969, ABBV-1480, alveltamig, EmrelisTM and Elahere.